Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7%# EBITDA at Rs 787 …

Jan 30, 2025 · Financial Commentary: Q3FY25. Consolidated Total Revenue for Q3FY25 was at Rs 3,856 crore.Reported 7% YoY growth on a like-for-like basis, after adjusting for Branded …

CouponFollow Extension

7%
OFF

Biocon Q3FY25 Revenue At Rs 3,856 Cr, Up 7%# EBITDA At Rs 787 …

2 weeks from now

Jan 30, 2025 · Financial Commentary: Q3FY25. Consolidated Total Revenue for Q3FY25 was at Rs 3,856 crore.Reported 7% YoY growth on a like-for-like basis, after adjusting for Branded …

biocon.com

7%
OFF

Biocon Q3FY25 Revenue At Rs 3,856 Cr, Up 7%# EBITDA At Rs …

2 weeks from now

Jan 30, 2025 · Biocon Q3FY25 Revenue at Rs 3,856 #Cr, Up 7% EBITDA at Rs 787 Cr, Up 16%#; Net Profit at Rs 25 Cr Biosimilars^ Up 14%; Research Services Up 11% Bengaluru, …

biocon.com

96%
OFF

Biocon Q3 Results: PAT Plunges 96% To ₹25 Cr; Revenue Up 7%

2 weeks from now

Jan 30, 2025 · Biocon’s Q3 PAT plunges 96% to ₹25 crore; revenue up 7% Updated - January 31, 2025 at 12:01 PM. In other news, Mayank Verma, Company Secretary, will resign on April 14.

thehindubusinessline.com

7%
OFF

Biocon Biologics - Transforming Healthcare. Transforming Lives.

2 weeks from now

Jan 30, 2025 · Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7% # EBITDA at Rs 787 Cr, Up 16% #; Net Profit at Rs 25 Cr. Jan 30, 2025. Biocon’s S&P Global ESG Score Improves to 69 for …

bioconbiologics.com

7%
OFF

Press Releases - Biocon Biologics - Global Biopharmaceutical …

2 weeks from now

Jan 30, 2025 · Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7% # EBITDA at Rs 787 Cr, Up 16% #; Net Profit at Rs 25 Cr. Jan 30, 2025 Biocon’s S&P Global ESG Score Improves to 69 for …

bioconbiologics.com

96%
OFF

Biocon Q3 Results: Profit Plummets 96%; Misses Estimates

2 weeks from now

Jan 30, 2025 · Biocon Ltd.'s Q3FY25 consolidated net profit plummeted 96% to Rs 25 crore, falling short of analysts' estimates. Revenue declined 3.4% to Rs 3,821 crore. Biocon Ltd.'s …

ndtvprofit.com

4%
OFF

Biocon Ltd's Q3FY25 Quarter Results: Detailed Financial Insights ...

2 weeks from now

Jan 31, 2025 · Revenue. In the third quarter of fiscal year 2025, Biocon Ltd reported a total income of ₹3856.20 crores, which represents a 6.4% increase quarter-over-quarter from …

kotaksecurities.com

6%
OFF

F A C T S H E E T - Biocon.com

2 weeks from now

BIOCON LIMITED (CONSOLIDATED) PROFIT & LOSS STATEMENT (Rs. Crores) ... Revenue from operations # 3,821 3,590 6% Other income 35 33 7% TOTAL REVENUE 3,856 3,623 6% …

biocon.com

10%
OFF

Biocon Limited Q3 FY25 Earnings Call Transcript

2 weeks from now

growth with Generics growing by 10%, Research Services by 6% and Biosimilars 5%. Total group revenue for Q3 FY25 was INR 3,856 crore, a growth of 7% last year and 6% sequentially on a …

biocon.com

5%
OFF

Biocon Buys Back An Investor Stake In Biologics Unit, Posts Rs 25 …

2 weeks from now

Jan 30, 2025 · Biocon's board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected to complete by February 1, …

indiatimes.com

30%
OFF

Biocon Q1FY25 Revenue Up 30% At Rs 4,567 Cr EBITDA Up 117

2 weeks from now

Aug 8, 2024 · Financial Commentary: Q1FY25 . Total Consolidated Revenue for Q1FY25 grew 30% year-on-year (YoY) to Rs 4,567 crore.. Other Income includes proceeds of Rs 1,057 …

bioconbiologics.com

7%
OFF

Press Releases - Biocon - Global Biopharmaceutical Company

2 weeks from now

Jan 30, 2025 · Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7% # EBITDA at Rs 787 Cr, Up 16% #; Net Profit at Rs 25 Cr. Jan 30, 2025 Biocon’s S&P Global ESG Score Improves to 69 for …

biocon.com

7%
OFF

Biocon Q3FY25 Revenue At Rs 3,856 #Cr, Up 7% EBITDA At Rs …

2 weeks from now

Biocon Q3FY25 Revenue at Rs 3,856 #Cr, Up 7% EBITDA at Rs 787 Cr, Up 16%#; Net Profit at Rs 25 Cr Biosimilars^ Up 14%; Research Services Up 11% Bengaluru, Karnataka, India: …

biocon.com

8%
OFF

Q3FY25: Zydus Lifesciences Reports Rise In Profit By 30 Percent To …

2 weeks from now

3 days ago · The company's Consumer Wellness business registered revenues of Rs. 448.8 crore, up 13 % y-o-y with 4.8% volume growth. ... Q3FY25: Zydus Lifesciences reports rise in …

financialexpress.com

18%
OFF

Biocon Q3FY22 Revenue At Rs 2,223 Cr, Up 18%; EBITDA At Rs 537 …

2 weeks from now

Jan 20, 2022 · Q3FY22 Revenue at Rs 607 Crore, up 7% YoY, 15% QoQ Commenting on the Generics segment performance, Siddharth Mittal, CEO & Managing Director, Biocon Limited , …

bioconbiologics.com

FAQs about Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7%# EBITDA at Rs 787 … Coupon?

What were Biocon's Q2FY21 financial results?

Biocon's Q2FY21 financial results: Revenue at Rs 1,760 Cr, Up 10%. EBITDA at Rs 407 Cr. Net Profit (before exceptional item & discontinuing operations) at Rs 174 Cr. Generics revenue was Rs 599 Cr, Up 8%. Biosimilars revenue was Rs 676 Cr, Up 11%. Research Services revenue was Rs 520 Cr, Up 12%. ...

What was Biocon's net profit in q3fy25?

Bengaluru-based biopharma firm Biocon on Thursday reported a consolidated net profit of Rs 25.1 crore in the third quarter of the financial year 2024-25 (Q3FY25). During the same period in the previous financial year, the company reported a loss of Rs 16 crore. ...

How did Biocon perform in q1fy25?

“ Biocon has reported consolidated revenues of Rs 4,567 crore for Q1FY25, delivering a strong 30% YoY growth, with EBITDA growing 117% to Rs 1,755 crore and a Net Profit of Rs 660 crore. This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences. ...

How did Biocon biologics & Eris Lifesciences perform in q1fy25?

Note: *Q1FY25 Consolidated Revenue includes proceeds of Rs 1057 Cr on account of the strategic collaboration between Biocon Biologics & Eris Lifesciences. “ Biocon has reported consolidated revenues of Rs 4,567 crore for Q1FY25, delivering a strong 30% YoY growth, with EBITDA growing 117% to Rs 1,755 crore and a Net Profit of Rs 660 crore. ...

How did Biocon perform in a quarter last year?

In the corresponding quarter last year, Biocon's earnings included revenue from the Branded Formulations India (BFI) business, which has since been divested, along with an income of ₹350 crore from the partial divestment of BFI units by Biocon Biologics and a gain of ₹456 crore from Biocon’s stake dilution in Bicara Therapeutics. ...

Why did Biocon grow 10 per cent sequential revenue?

Siddharth Mittal, chief executive officer and managing director, Biocon, noted, “The 10 per cent sequential revenue growth in the generics business was primarily driven by API sales, supported by an improved performance from generic formulations. We expect to see an improved performance in the quarters ahead.” ...